What is PharmaCann?
Established in 2014, PharmaCann operates at the intersection of pharmaceutical rigor and consumer wellness. The company is dedicated to the discovery, production, and responsible dispensing of cannabis-related products, with a core mission to improve patient quality of life through evidence-based science. Headquartered in Chicago, Illinois, PharmaCann distinguishes itself by prioritizing a clinical understanding of cannabis impacts, aiming to bridge the gap between traditional healthcare and emerging botanical therapies. Its market position is defined by a focus on high-quality production standards and a commitment to professionalized, state-licensed operations.
How much funding has PharmaCann raised?
PharmaCann has raised a total of $194.9M across 3 funding rounds:
Corporate Investment
$110.4M
Debt
$39.5M
Other Financing Round
$45M
Corporate Investment (2021): $110.4M with participation from The Cronos Group
Debt (2022): $39.5M, investors not publicly disclosed
Other Financing Round (2022): $45M supported by Innovative Industrial Properties
Key Investors in PharmaCann
The Cronos Group
Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. The company was founded in 2012 and is headquartered in Toronto, Ontario.
Innovative Industrial Properties
Innovative Industrial Properties, Inc. is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated cannabis facilities.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for PharmaCann?
With the recent infusion of capital, PharmaCann is well-positioned to accelerate its strategic objectives, particularly in the areas of facility optimization and market penetration. The company is expected to utilize these funds to enhance its production capabilities and deepen its research into the therapeutic applications of cannabinoids. As the regulatory environment for cannabis continues to mature, PharmaCann's focus on science-led innovation will likely serve as a key differentiator, enabling the firm to capture additional market share and establish new benchmarks for quality and safety in the wellness sector. Future growth will likely center on scaling its distribution network and refining its product portfolio to meet the increasing demand for specialized, regulated cannabis solutions.
See full PharmaCann company page
